生产企业：Scholar Rock
Apitegromab (brand name Isembyld, apitegromab-mstn) is a muscle-targeted therapy developed by Scholar Rock. It was approved by the FDA for spinal muscular atrophy (SMA) in patients 2 years of age and older, becoming the first SMA therapy that directly targets muscle loss rather than motor neurons.
Apitegromab (brand name Isembyld, apitegromab-mstn) is a muscle-targeted therapy developed by Scholar Rock. It was approved by the FDA for spinal muscular atrophy (SMA) in patients 2 years of age and older, becoming the first SMA therapy that directly targets muscle loss rather than motor neurons.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
